Keryx Biopharm Inc (KERX) 4.72 $KERX Downgrade Alert for

New Post Public Reply Private Reply Replies (0) Message Board

Aug 2, 2016 at 6:05 AM

Keryx Biopharm Inc (KERX) 4.72 $KERX

Downgrade Alert for Keryx Biopharmaceuticals (KERX)
Comtex SmarTrend(R) - 2 hrs 1 min ago
Keryx Biopharmaceuticals (NASDAQ:KERX) was downgraded from Buy to Hold at Stifel today. The stock closed yesterday at $4.72 on volume of 14.0 million shares, above average daily volume of 2.1 million. Keryx Biopharmaceuticals, Inc. is a biopharmaceutical company focused on the acquisition, development, and commercialization of novel pharmaceutical products for the treatment of life-threatening diseases, including diabetes and cancer. Keryx is developing KRX-101 (sulodexide), a novel first-in-class oral heparinold compound for the treatment of diabetic nephropathy.
KERX: 4.72 (-2.64)

INVESTOR NOTICE: Goldberg Law PC Announces an Investigation of Claims Against Keryx Biopharmaceuticals Inc. and Advises Investors with Losses to Contact the Firm
BusinessWire - Mon Aug 01, 7:53PM CDT
Goldberg Law PC (http://www.Goldberglawpc.com) announces that it is investigating Keryx Biopharmaceuticals Inc. ("Keryx" or the "Company"

(Nasdaq: KERX) concerning possible violations of federal securities laws.
KERX: 4.72 (-2.64)

Glancy Prongay & Murray Commences Investigation on Behalf of Keryx Pharmaceuticals, Inc. Investors
BusinessWire - Mon Aug 01, 5:41PM CDT
Glancy Prongay & Murray LLP ("GPM"

announces an investigation on behalf of investors of Keryx Pharmaceuticals, Inc. ("Keryx" or the "Company"

(NASDAQ: KERX) concerning the Company and its officers' possible violations of federal securities laws. GPM is preparing a lawsuit on behalf of injured investors.
KERX: 4.72 (-2.64)

Keryx Biopharmaceuticals Falls 30.57% on Heavy Volume: Watch For Potential Rebound
Comtex SmarTrend(R) - Mon Aug 01, 3:47PM CDT
Keryx Biopharmaceuticals (NASDAQ:KERX) traded in a range yesterday that spanned from a low of $4.81 to a high of $5.35. Yesterday, the shares fell 30.6%, which took the trading range below the 3-day low of $7.25 on volume of 8.3 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
KERX: 4.72 (-2.64)

Keryx (KERX) Q2 Loss Wider than Expected, Withdraws View
Zacks Equity Research - Zacks Investment Research - Mon Aug 01, 8:22AM CDT
Keryx (KERX) reported a loss of 42 cents in second-quarter of 2016, above the Zacks Consensus Estimate of 29 cents.
KERX: 4.72 (-2.64)

Keryx Biopharmaceuticals Announces Interruption in Supply of Auryxia(R) (ferric citrate) and Second Quarter 2016 Financial Results
GlobeNewswire - Mon Aug 01, 6:30AM CDT
- Supply interruption does not affect the safety profile of currently available Auryxia -
KERX: 4.72 (-2.64)

Keryx (KERX) Q2 Earnings Preview: Will the Stock Gain?
Zacks Equity Research - Zacks Investment Research - Fri Jul 29, 4:13PM CDT
Keryx Biopharmaceuticals, Inc. (KERX) is expected to report second-quarter 2016 results on Aug 3.
IPXL: 31.15 (-0.27), IRWD: 13.94 (-0.19), KERX: 4.72 (-2.64), EXEL: 9.27 (+0.09)

Keryx Biopharmaceuticals to Host Conference Call of Second Quarter 2016 Financial Results on Monday, August 1, 2016
GlobeNewswire - Fri Jul 29, 7:30AM CDT
Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX), a biopharmaceutical company focused on bringing innovative medicines to people with renal disease, today announced that it will host a conference call and webcast on Monday, August 1, 2016 at 8:30 a.m. ET to discuss its second quarter 2016 financial results and provide a company update.
KERX: 4.72 (-2.64)

Keryx Biopharmaceuticals Up 64.8% Since SmarTrend Uptrend Call (KERX)
Comtex SmarTrend(R) - Wed Jul 27, 12:44PM CDT
SmarTrend identified an Uptrend for Keryx Biopharmaceuticals (NASDAQ:KERX) on March 2nd, 2016 at $4.49. In approximately 5 months, Keryx Biopharmaceuticals has returned 64.77% as of today's recent price of $7.39.
KERX: 4.72 (-2.64)

Keryx Biopharma, Waddell & Reed Financial, Benchmark Electronics, Ryerson Holding and Wex highlighted as Zacks Bull and Bear of the Day
Zacks Equity Research - Zacks Investment Research - Tue Jul 26, 8:30AM CDT
Keryx Biopharma, Waddell & Reed Financial, Benchmark Electronics, Ryerson Holding and Wex highlighted as Zacks Bull and Bear of the Day
RYI: 14.67 (+0.23), BHE: 23.64 (+0.20), WEX: 91.96 (-1.72), WDR: 18.37 (+0.11), KERX: 4.72 (-2.64)

Bull of the Day: Keryx Biopharma (KERX)
Brian Bolan - ZACKS - Tue Jul 26, 7:12AM CDT
Bull of the Day: Keryx Biopharma (KERX)
KERX: 4.72 (-2.64)

Momenta Pharmaceuticals Appoints Steven C. Gilman, Ph.D. to Board of Directors
GlobeNewswire - Thu Jun 23, 7:00AM CDT
Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today announced the appointment of Steven C. Gilman, Ph.D. to its Board of Directors effective June 22, 2016. Dr. Gilman was most recently Executive Vice President, Research & Development and Chief Scientific Officer at Cubist Pharmaceuticals, until its acquisition by Merck & Co. in January 2015.
VCEL: 2.22 (-0.04), SCYX: 2.00 (-0.02), CFRX: 2.40 (unch), MNTA: 11.34 (+0.08), KERX: 4.72 (-2.64)

Keryx Biopharmaceuticals Has Returned 37.7% Since SmarTrend Recommendation (KERX)
Comtex SmarTrend(R) - Fri Jun 17, 12:55PM CDT
SmarTrend identified an Uptrend for Keryx Biopharmaceuticals (NASDAQ:KERX) on March 2nd, 2016 at $4.49. In approximately 4 months, Keryx Biopharmaceuticals has returned 37.73% as of today's recent price of $6.18.
KERX: 4.72 (-2.64)

Shares of KERX Up 34.9% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Fri Jun 10, 12:31AM CDT
SmarTrend identified an Uptrend for Keryx Biopharmaceuticals (NASDAQ:KERX) on March 2nd, 2016 at $4.49. In approximately 3 months, Keryx Biopharmaceuticals has returned 34.89% as of today's recent price of $6.05.
KERX: 4.72 (-2.64)

Shares of KERX Up 53.8% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Thu Jun 02, 1:04PM CDT
SmarTrend identified an Uptrend for Keryx Biopharmaceuticals (NASDAQ:KERX) on March 2nd, 2016 at $4.49. In approximately 3 months, Keryx Biopharmaceuticals has returned 53.85% as of today's recent price of $6.90.
KERX: 4.72 (-2.64)

Keryx Biopharmaceuticals Up 22.4% Since SmarTrend Uptrend Call (KERX)
Comtex SmarTrend(R) - Wed May 18, 1:20PM CDT
SmarTrend identified an Uptrend for Keryx Biopharmaceuticals (NASDAQ:KERX) on March 2nd, 2016 at $4.49. In approximately 3 months, Keryx Biopharmaceuticals has returned 22.41% as of today's recent price of $5.49.
KERX: 4.72 (-2.64)

Uptrend Call Working As Keryx Biopharmaceuticals Stock Rises 27.1% (KERX)
Comtex SmarTrend(R) - Tue May 03, 12:56PM CDT
SmarTrend identified an Uptrend for Keryx Biopharmaceuticals (NASDAQ:KERX) on March 2nd, 2016 at $4.49. In approximately 2 months, Keryx Biopharmaceuticals has returned 27.09% as of today's recent price of $5.70.
KERX: 4.72 (-2.64)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Beasley and Vegas Golden Knights Partner for Broadcast

Strategic Moves on the Airwaves The Vegas Golden Knights are skating into a new era of broadcasting. Teaming up with Beasley Media Group, they've inked a multiyear deal that makes the media outfit their official audio partner. Dropping the puck on this relationship means folks in Southern Nevada can catch the action on Beasley's English and Spanish stations. It's a hefty...

Celina Graves Joins Expanding GoLive Streamers Platform

Celina Graves Breaks New Ground on GoLive Streamers You'd think television capture all the talent buzz, but nope. Celina Graves, known from her semifinalist run on America's Got Talent, is diving into new waters by joining GoLive Streamers. She's stirring up the scene by making her performances more personal, stretching beyond the flatness of your typical TV appearance....

Understanding Criminal Threat Charges in Kansas

The Intricacies of Criminal Threat Cases in Kansas Let's cut straight to it: not all heated exchanges land you in court, but words can slap you with a criminal threat charge in Kansas if mishandled. A simple spat can turn legal nightmare, making it crucial to grasp the nuances of these cases. What sets them apart from other charges is the absence of physical...

BLM's Wild Horse Strategy: Fertility Control's Time to Shine

Wild Horse Management Gets a Shot in the Arm Amigo, when the federal government throws $30 million dollars at a problem, you'd hope they're not just throwing us a bone. The Bureau of Land Management (BLM) now has this hefty sum courtesy of the U.S. Department of Agriculture, intended to expand wild horse fertility control across the sprawling landscapes they roam. This...

Schneider Electric Pushes Water Management Tech at WEFTEC

Looks like Schneider Electric is diving headfirst into the choppy waters of utility management with its latest tech showcase at WEFTEC 2026. And trust me, the timing couldn't be more spot-on. With North America's water and wastewater systems groaning under the weight of aging infrastructure and cybersecurity threats, it’s about time someone brought something fresh to...

SOA Elects New Leaders for 2026: A Look Ahead

A New Lineup for SOA's Board in 2026 On the financial frontlines, few organizations hold the clout that the Society of Actuaries (SOA) wields. With their latest round of elections completed, they've named five fresh Board members along with both a new President Elect and Vice Chair for the upcoming 2026-2027 term. These folks are gearing up to take the stage right after...

HiBy Unveils Cyberpunk 2077 Gaming Audio Line

HiBy Hits the Gaming Scene with Cyberpunk Flair It's a wild world when audio tech and gaming collide outside of the usual suspects. HiBy's latest move is a bold pivot into the gaming universe, launching an audacious collaboration with, of all things, the cybernetic chaos of Cyberpunk 2077. You can almost feel the underlying scrappiness of Night City embedded into a couple...

Klydoclock's Bold Move: Licensing International Boost

Revolutionizing Timekeeping with Art There’s this clock outfit, Klydoclock, that’s flipping the script on how we see time and art melding together. You see, they’ve taken those static old tick-tock reminders of the hour and juiced 'em up with animated art, turning your wall clock into something more akin to a mini art exhibit right in your living room. Ever heard of...

AHN Healthcare@Home Celebrates Fourth Top Workplace Win

Four-Time Top Workplace Champ You want to talk consistency? Let's talk about AHN Healthcare@Home pulling in that Pittsburgh Top Workplace award four years running. It's no small feat, especially in the healthcare sector where employee burnout isn't just a buzzword—it's a daily challenge. How did a home health and hospice outfit like AHN land this honor? Well, it's all...

LifeLabs' AI Program: A Manager's New Toolbox

Management In the Age of AI: New Frontiers Gone are the days when a simple software update meant staying competitive. We're in a new era, folks—one where AI isn't just a handy tool—it's reshaping entire industries. But here's the kicker: all the fancy tech in the world won't do squat without savvy managers who know how to drive adoption. Yup, that's the naked truth,...